OncoGenex (OGXI)

Company Description

OncoGenex is a biopharmaceutical company uniquely focused on cancer treatment resistance. The company is developing innovative therapies that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.


1522 217th Place SE
Bothell, Washington 98021
United States



Get BioInvest's perspective on OncoGenex's CEO

Latest Company News

BRIEF-Oncogenex Pharmaceuticals says clinical data from trials in bladder and ... Reuters - 23 hours ago Feb 21 Oncogenex Pharmaceuticals Inc: * Oncogenex Pharmaceuticals, Inc. announces phase 2 apatorsen data for two clinical trials presented at the American Society Of Clinical Oncology (asco) 2017 genitourinary cancers symposium. OncoGenex Pharmaceuticals Inc. - Receive News & Ratings Daily - BBNS OncoGenex Pharmaceuticals Inc. (OGXI) Reviewed By Analysts - The De Soto Edge [...]
Tue, Feb 21, 2017 2:15:00 PM, Continue reading at the source
OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two ... Yahoo Finance - 23 hours ago 21, 2017 /CNW/ -- OncoGenex Pharmaceuticals, Inc. (OGXI) today announced that apatorsen results from two randomized Phase 2 clinical trials were presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium, ... [...]
Tue, Feb 21, 2017 2:08:00 PM, Continue reading at the source
Research Reports Coverage on Biotech Stocks -- OncoGenex Pharma, INSYS ... Yahoo Finance - Jan 26, 2017 This morning, Stock-Callers.com explores the Biotech industry to see how some equities have been faring. Under evaluation today are: OncoGenex Pharmaceuticals Inc. (OGXI), INSYS Therapeutics Inc. (INSY), Threshold Pharmaceuticals Inc. (THLD), and ... [...]
Thu, Jan 26, 2017 12:11:00 PM, Continue reading at the source
OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) Announces Merger – Shares Higher StockNewsUnion - Jan 6, 2017 OncoGenex Pharmaceuticals, Inc. shares, traded on the Nasdaq under ticker OGXI, are up over 50% on heavy volumes. OncoGenex develops novel therapeutics that target important mechanisms of treatment resistance in cancer with the potential to redefine ... OncoGenex Pharmaceuticals (OGXI) Stock: Surges 48%+ On Merger - CNA Finance (press release) Reverse merger will see Achieve Life Science acquired by OncoGenex - The Pharma Letter (registration) [...]
Fri, Jan 06, 2017 3:00:00 PM, Continue reading at the source
BRIEF-Oncogenex Pharmaceuticals and Achieve Life Science announce definitive ... Reuters - Jan 5, 2017 SEOUL, Feb 18 Handcuffed and tied with white rope, the scion of one of the world's biggest conglomerates, Samsung Group, was taken on Saturday for questioning by South Korean authorities after spending a night in a small detention cell. [...]
Thu, Jan 05, 2017 9:56:00 PM, Continue reading at the source
OncoGenex Pharma (OGXI) Announces Custirsen Phase 3 Missed Primary Endpoint in ... StreetInsider.com - Aug 16, 2016 OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with ... OncoGenex seeks strategic alternatives after drug study fails - Reuters OncoGenex (OGXI) Stock Nosedives after Failing Yet Another Trial - Economic Calendar [...]
Tue, Aug 16, 2016 11:03:00 AM, Continue reading at the source
OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q2 2016 Results ... Seeking Alpha - Aug 5, 2016 These statements are only predictions, and actual results may vary materially from those projected. Please refer to OncoGenex's documents filed with the SEC concerning factors that could affect the company, copies of which are available on the website. [...]
Fri, Aug 05, 2016 12:22:00 AM, Continue reading at the source
Ionis Pharma and OncoGenex in tussle over money Seeking Alpha - Jan 7, 2016 In a regulatory filing, OncoGenex Pharmaceuticals (NASDAQ:OGXI) discloses that Ionis Pharmaceuticals (NASDAQ:IONS) has filed a lawsuit against its subsidiary OncoGenex Technologies seeking a portion of $23.2M it received from Teva Pharmaceutical ... [...]
Thu, Jan 07, 2016 9:22:00 PM, Continue reading at the source
OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following ... PR Newswire (press release) - Dec 1, 2015 1, 2015 /PRNewswire/ -- Following an independent Data Monitoring Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that its Phase 3 AFFINITY trial is continuing based on the pre-planned interim futility ... Analysts Weigh In On Two Collapsing Biotechs: Zafgen Inc (ZFGN), OncoGenex ... - Smarter Analyst OncoGenex Pharma's (OGXI) Phase 3 AFFINITY Trial with Custirsen to Continue ... - StreetInsider.com [...]
Tue, Dec 01, 2015 9:09:00 PM, Continue reading at the source
OncoGenex Pharmaceuticals: In The Midst Of A Possible Turnaround Seeking Alpha - Jun 4, 2015 Today's small cap focus stock is OncoGenex Pharmaceuticals, which has two drugs in development and a market capitalization of just over $50 million. [...]
Thu, Jun 04, 2015 4:03:00 AM, Continue reading at the source